Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, iBio, Inc. reported revenue of $0M, up 77.8% year over year. Operating margin was -4650.5% and net margin -4594.3%, on a free-cash-flow margin of -3830.0% with capital expenditure at 4.0% of revenue. Every figure is computed directly from IBIO's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $0M | -4650.5% | -4594.3% |
| FY2024 | $0M | -7392.9% | -11069.8% |
| FY2023 | $0M | n/a | n/a |
| FY2022 | $2M | -1576.3% | -2670.0% |
| FY2021 | $2M | -1312.1% | -978.8% |
How does IBIO compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.